OBJECTIVE: The purpose of this study was to investigate maternal plasma concentrations of asymmetric dimethylarginine (ADMA) in mid pregnancy and at the time of disease in women who experience preeclampsia, compared with women with uncomplicated pregnancies and women with small-for-gestational-age infants. STUDY DESIGN: Plasma samples were collected at mid-pregnancy and at the time of delivery from 31 women with uncomplicated pregnancies, from 12 women with small-for-gestational-age infants, and from 15 women with preeclampsia. ADMA and L-arginine concentrations were measured using high-pressure liquid chromatography. RESULTS: Maternal ADMA concentrations were elevated at mid pregnancy and remained elevated at delivery in women who later experienced preeclampsia (0.45 +/- 0.09 micromol/L) compared with women with uncomplicated pregnancies (0.34 +/- 0.08 micromol/L; P < .01) and with women with small-for-gestational-age infants (0.33 +/- 0.06 micromol/L; P < .01). CONCLUSION: Maternal ADMA concentrations are higher in mid pregnancy in women who experience preeclampsia, compared with women with uncomplicated pregnancies and small-for-gestational-age infants. Elevated ADMA concentration before clinical onset of preeclampsia suggests a role of this nitric oxide synthase inhibitor in the pathophysiologic condition of preeclampsia.
OBJECTIVE: The purpose of this study was to investigate maternal plasma concentrations of asymmetric dimethylarginine (ADMA) in mid pregnancy and at the time of disease in women who experience preeclampsia, compared with women with uncomplicated pregnancies and women with small-for-gestational-age infants. STUDY DESIGN: Plasma samples were collected at mid-pregnancy and at the time of delivery from 31 women with uncomplicated pregnancies, from 12 women with small-for-gestational-age infants, and from 15 women with preeclampsia. ADMA and L-arginine concentrations were measured using high-pressure liquid chromatography. RESULTS: Maternal ADMA concentrations were elevated at mid pregnancy and remained elevated at delivery in women who later experienced preeclampsia (0.45 +/- 0.09 micromol/L) compared with women with uncomplicated pregnancies (0.34 +/- 0.08 micromol/L; P < .01) and with women with small-for-gestational-age infants (0.33 +/- 0.06 micromol/L; P < .01). CONCLUSION: Maternal ADMA concentrations are higher in mid pregnancy in women who experience preeclampsia, compared with women with uncomplicated pregnancies and small-for-gestational-age infants. Elevated ADMA concentration before clinical onset of preeclampsia suggests a role of this nitric oxide synthase inhibitor in the pathophysiologic condition of preeclampsia.
Authors: J Ellis; U B Wennerholm; A Bengtsson; H Lilja; A Pettersson; B Sultan; M Wennergren; H Hagberg Journal: Acta Obstet Gynecol Scand Date: 2001-07 Impact factor: 3.636
Authors: Vinod Achan; Michael Broadhead; Mohammed Malaki; Guy Whitley; James Leiper; Raymond MacAllister; Patrick Vallance Journal: Arterioscler Thromb Vasc Biol Date: 2003-06-12 Impact factor: 8.311
Authors: Carmen A H Severens-Rijvers; Salwan Al-Nasiry; Annemiek Vincken; Guido Haenen; Bjorn Winkens; Chahinda Ghossein-Doha; Marc A E Spaanderman; Louis L H Peeters Journal: Gynecol Obstet Invest Date: 2019-07-29 Impact factor: 2.031
Authors: Fernando Holguin; Suzy A A Comhair; Stanley L Hazen; Robert W Powers; Sumita S Khatri; Eugene R Bleecker; William W Busse; William J Calhoun; Mario Castro; Anne M Fitzpatrick; Benjamin Gaston; Elliot Israel; Nizar N Jarjour; Wendy C Moore; Stephen P Peters; W Gerald Teague; Kian Fan Chung; Serpil C Erzurum; Sally E Wenzel Journal: Am J Respir Crit Care Med Date: 2012-11-29 Impact factor: 21.405